Eisai's Alzheimer's Treatment Receives Agreement For Approval In 12 European Countries
Tokyo (July 15, 1997) - Eisai Co., Ltd. (President and CEO: Haruo Naito) today announced that the Eisai developed Alzheimer's disease treatment, ARICEPT(TM) (donepezil hydrochloride or E2020), a once daily dosed new drug for the symptomatic treatment of mild to moderate Alzheimer's disease, received agreement for approval in 12 countries in Europe through the mutual recognition procedure.
ARICEPT(TM) received agreement for approval in Germany, France, Italy, Austria, Belgium, Luxembourg, Denmark, Finland, Greece, Ireland, Portugal, and Sweden. Pharmaceutical authorities in each country will issue marketing authorizations in the near future.
ARICEPT(TM) is a new reversible acetylcholinesterase inhibitor synthesized by Eisai in Japan, and is being developed by Eisai in Japan, Europe and in the US. ARICEPT(TM) was approved for marketing by the US Food and Drug Administration (FDA) in November 1996, and Eisai began marketing in January, 1997. Within Europe, ARICEPT(TM) received marketing authorization in the U.K. in February, and in Switzerland in May 1997. ARICEPT(TM) is in the Phase III clinical trial stage in Japan.
Through co-promotion with Pfizer Inc, Eisai markets ARICEPT(TM) in the U.S. and U.K. and will also market in Germany and France.
Eisai Co., Ltd. is a research-based human health care company which discovers, develops and markets products in more than 30 countries. Through its global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care systems. The company reported consolidated sales of $2.3 billion in 1996 with approximately 14 percent of sales spent for research and development.
ARICEPT(TM) is a trademark of Eisai Co., Ltd.